Ser⁷⁸⁴ phosphorylation: a clinically relevant enhancer of VCP function in the DNA damage response

ABSTRACT

Valosin-containing protein (VCP) is essential for proteostasis during many cellular processes. However, it remains uncertain how its diverse functions are selectively regulated. We recently showed that DNA damage-induced Ser⁷⁸⁴ phosphorylation specifically increases VCP function for the DNA damage response and significantly influences the survival of chemotherapy-treated breast cancer patients.

KEYWORDS:

• Proteostasis
• DNA damage response
• chemotherapy
• phosphorylation
• prognostic biomarker

Disclosure of potential conflicts of interest

Provisional patent has been filed for the monoclonal pSer⁷⁸⁴-VCP antibody as a predictive biomarker for cancer chemotherapies.

Additional information

Funding

This work was funded by National Cancer Institute (5R01CA181671); Alvin J. Siteman Cancer Center; Longer Life Foundation;Susan G. Komen Foundation [CCR14300139].